Updated on 2024/03/25

写真a

 
TOKUDA Emi
 
Organization
School of Medicine (Clinical Medicine) Department of Medical Oncology Associate Professor
Title
Associate Professor

Research History

  • Fukushima Medical University   School of Medicine (Clinical Medicine) Department of Medical Oncology   Associate Professor

    2018.11 - Now

Papers

  • The Impact of Being Underweight on the Prognosis of Older Patients With Early Breast Cancer.

    Ishizuka Y, Horimoto Y, Morita M, Kawamura Y, Sekine K, Obayashi S, Kojima Y, Tokuda E, Higuchi T, Shimomura A.

    Cancer Diagn Progn.   3 ( 6 )   678 - 686   2023.11

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.21873/cdp.10272.

  • The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition.

    Terada M, Ito A, Kikawa Y, Koizumi K, Naito Y, Shimoi T, Ishihara M, Yamanaka T, Ozaki Y, Hara F, Nakamura R, Hattori M, Miyashita M, Kondo N, Yoshinami T, Takada M, Matsumoto K, Narui K, Sasada S, Iwamoto T, Hosoda M, Takano Y, Oba T, Sakai H, Murakami A, Higuchi T, Tsuchida J, Tanabe Y, Shigechi T, Tokuda E, Harao M, Kashiwagi S, Mase J, Watanabe J, Nagai SE, Yamauchi C, Yamamoto Y, Iwata H, Saji S, Toyama T.

    Breast Cancer.   2023.11

      More details

    Authorship:Last author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1007/s12282-023-01505-x.

  • E3 Ubiquitin Ligase NEDD4 Affects Estrogen Receptor α Expression and the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer

    Natori Y, Suga J, Tokuda E, Tachibana K, Imai J, Honma R, Azami Y, Noda M, Sasaki E, Watanabe S, Ohtake T, Saji S.

    Cancers   15 ( 2 )   539   2023.1

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.3390/cancers15020539

  • Successful management of pelvic recurrence of MSI-High endometrial cancer by total pelvic exenteration followed by administration of pembrolizumab:A case report.

    Kojima M, Soeda S, Okabe C, Sato T, Kamo N, Ueda M, Endo Y, Nomura S, Tokuda E, Furukawa S, Kataoka M, Fujita S, Saji S, Watanabe T, Fujimori K.

    Fukushima J Med Sci.   15 ( 2 )   539   2022.12

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.5387/fms.2022-10.

  • Is adjuvant chemotherapy necessary in older patients with breast cancer?

    Morita M, Shimomura A, Tokuda E, Horimoto Y, Kawamura Y, Ishizuka Y, Sekine K, Obayashi S, Kojima Y, Uemura Y, Higuchi T.

    Breast Cancer.   29 ( 3 )   498 - 506   2022.5( ISSN:1340-6868

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1007/s12282-021-01329-7.

  • Everolimus+Exemestane療法後に腫瘍崩壊症候群をきたした進行乳癌の一例

    竹村 真生子, 岡崎 護, 羽成 直行, 徳田 恵美, 田辺 真彦, 林 嗣博, 水谷 知央, 林 孝朗, 中村 優飛, 根本 悠里, 佐久間 芽衣, 叶多 諒, 萩尾 浩太郎, 絹田 俊爾, 山口 佳子, 輿石 直樹

    福島医学雑誌   71 ( 1 )   35 - 40   2021.4( ISSN:0016-2582

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Risk of immunotherapy-related narcolepsy in genetically predisposed patients: a case report of narcolepsy after administration of pembrolizumab.

    Natori Y, Sasaki E, Soeda S, Furukawa S, Azami Y, Tokuda E, Kanbayashi T, Saji S

    Journal for immunotherapy of cancer   8 ( 2 )   2020.10

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1136/jitc-2020-001164

    PubMed

  • Decreased ER dependency after acquired resistance to CDK4/6 inhibitors

    Iida Masafumi, Toyosawa Daichi, Nakamura Misato, Tsuboi Kouki, Tokuda Emi, Niwa Toshifumi, Ishida Takanori, Hayashi Shin-ichi

    Breast Cancer   27 ( 5 )   963 - 972   2020.9( ISSN:1340-6868

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1007/s12282-020-01090-3.

  • Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.

    Horimoto Yoshiya, Hlaing May Thinzar, Saeki Harumi, Kitano Shigehisa, Nakai Katsuya, Sasaki Ritsuko, Kurisaki-Arakawa Aiko, Arakawa Atsushi, Otsuji Naomi, Matsuoka Shuji, Tokuda Emi, Arai Masami, Saito Mitsue

    Cancer Science   111 ( 7 )   2647 - 2654   2020.7( ISSN:1347-9032

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1111/cas.14500

  • 分子標的治療薬の副作用と支持療法 CDK4/6阻害薬

    徳田 恵美

    腫瘍内科   25 ( 3 )   257 - 264   2020.3

      More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 食道狭窄をきたした高齢者転移性乳癌に集学的治療が著効した1例

    魚森 俊喬, 徳田 恵美, 堀本 義哉, 齊藤 光江

    日本外科系連合学会誌   44 ( 6 )   1031 - 1035   2019.12( ISSN:0385-7883

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Impact of circulating tumour cells on survival of eribulin-treated patients with metastatic breast cancer.

    Ito M, Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Saito M.

    Med Oncol.   36 ( 10 )   89   2019.9

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1007/s12032-019-1314-9.

  • The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer.

    Iida M, Nakamura M, Tokuda E, Toyosawa D, Niwa T, Ohuchi N, Ishida T, Hayashi SI

    Oncotarget.   10 ( 47 )   4907 - 4918   2019.8

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.18632/oncotarget.27127.

    PubMed

  • 【エストロゲン受容体陽性転移乳癌の薬物療法】CDK4/6阻害薬

    徳田 恵美, 佐治 重衡

    日本内分泌外科学会誌   36 ( 2 )   101 - 106   2019.6

      More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.

    Horimoto Y, Tokuda E, Murakami F, Uomori T, Himuro T, Nakai K, Orihata G, Iijima K, Togo S, Shimizu H, Saito M.

    J Transl Med.   16 ( 1 )   287   2018.10

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1186/s12967-018-1663-8.

    PubMed

  • Overcoming the Adverse Effects of Everolimus to Achieve Maximum Efficacy in the Treatment of Inoperable Breast Cancer: A Review of 11 Cases at Our Hospital

    Yoshida-Ichikawa Y, Tanabe M, Tokuda E, Shimizu H, Horimoto Y, Miura K, Saito M.

    Case Rep Oncol.   11 ( 2 )   511 - 520   2018.7

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1159/000490787.

    PubMed

  • Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer.

    Okazaki M, Horimoto Y, Tanabe M, Ichikawa Y, Tokuda E, Arakawa A, Kobayashi T, Saito M.

    Med Oncol.   35 ( 4 )   48   2018.3

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1007/s12032-018-1112-9.

    PubMed

  • CDK6 might be a key factor for efficacy of CDK4/6 inhibitor and the hormone sensitivity following acquired resistance

    Iida Masafumi, Nakamura Misato, Tokuda Emi, Niwa Toshifumi, Ishida Takanori, Hayashi Shin-ichi

    CANCER RESEARCH   78 ( 4 )   2018.2( ISSN:0008-5472

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Effects of PI3K inhibitors on endocrine-resistant cell lines and differences in the characteristics of ER positive breast cancer cells after acquired resistance to the inhibitors

    Tokuda Emi, Komatsu Takayuki, Sasaki Shunta, Tsuboi Kouki, Nakamura Misato, Iida Masafumi, Niwa Toshifumi, Saito Mitsue, Hayashi Shin-Ichi

    CANCER RESEARCH   78 ( 4 )   2018.2( ISSN:0008-5472

      More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • MESENCHYMAL CIRCULATING TUMOUR CELL ANALYSIS TO PREDICT EFFICACY OF ERIBULIN FOR METASTATIC BREAST CANCER PATIENTS

    Yoshiya Horimoto, Emi Tokuda, Fumi Murakami, Katsuya Nakai, Hideo Shimizu, Mitsue Saito

    BREAST   36   S40 - S41   2017.11( ISSN:0960-9776

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer.

    Tokuda E, Horimoto Y, Arakawa A, Himuro T, Senuma K, Nakai K, Saito M.

    Hum Pathol.   63   40 - 45   2017.5

      More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1016/j.humpath

    PubMed

  • 【乳癌学-最新の診断と治療-】 乳癌の分子生物学と発症機序 乳癌のサブタイプ 分子機構と薬物療法概論 エストロゲン依存性乳癌の分子機構と内分泌療法

    林 慎一, 徳田 恵美

    日本臨床   75 ( 増刊3 )   112 - 117   2017.4( ISSN:0047-1852

      More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • ホルモン療法の感受性マーカー

    徳田 恵美, 林 慎一

    がん分子標的治療   15 ( 1 )   66 - 71   2017.3( ISSN:1347-6955

      More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

  • Tumor marking for breast-conserving surgery of non-palpable early breast cancer presenting microcalcifications

    M. Mori, E. Tokuda, Y. Horimoto, T. Uomori, F. Murakami, M. Tanabe, A. Shiraishi, A. Arakawa, K. Iijima, M. Saito

    BREAST   32   S119 - S119   2017.3( ISSN:0960-9776

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Activated Caspase 3 Expression in Remnant Disease After Neoadjuvant Chemotherapy May Predict Outcomes of Breast Cancer Patients.

    Himuro T, Horimoto Y, Arakawa A, Matsuoka J, Tokuda E, Tanabe M, Saito M.

    Ann Surg Oncol.   23 ( 7 )   2235 - 2241   2016.7

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1245/s10434-016-5164-9.

    PubMed

  • Caspase 3 expression in remnant disease after neo-adjuvant chemotherapy may predict outcomes of breast cancer patients

    T. Himuro, Y. Horimoto, A. Arakawa, E. Tokuda, M. Tanabe

    EUROPEAN JOURNAL OF CANCER   57   S43 - S43   2016.4( ISSN:0959-8049

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Menstrual cycle could affect Ki67 expression in estrogen receptor-positive breast cancer patients.

    Horimoto Y, Arakawa A, Tanabe M, Kuroda K, Matsuoka J, Igari F, Himuro T, Yoshida Y, Tokuda E, Shimizu H, Hino O, Saito M

    J Clin Pathol.   68 ( 10 )   825 - 829   2015.10

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1136/jclinpath-2015-203085.

    PubMed

  • 乳癌における上皮間葉転換 治療標的としての臨床応用の可能性

    猪狩 史江, 堀本 義哉, 吉田 悠子, 徳田 恵美, 清水 秀穂, 田辺 真彦, 齊藤 光江

    乳癌の臨床   30 ( 3 )   229 - 236   2015.6( ISSN:0911-2251

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.

    Shimizu H, Horimoto Y, Arakawa A, Sonoue H, Kurata M, Kosaka T, Nakai K, Himuro T, Tokuda E, Takahashi Y, Taira F, Ito M, Abe I, Senuma K, Stork-Sloots L, de Snoo F, Saito M

    Mol Clin Oncol   10 ( 2 )   118 - 122   2015.4

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1159/000376562.

    PubMed

  • Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases,

    Horimoto Y, Arakawa A, Harada-Shoji N, Sonoue H, Yoshida Y, Himuro T, Igari F, Tokuda E, Mamat O, Tanabe M, Hino O, Saito M

    Br J Cancer,   112 ( 2 )   345 - 351   2015.1

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1038/bjc.2014.595.

  • Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer.

    Horimoto Y, Arakawa A, Tanabe M, Sonoue H, Igari F, Senuma K, Tokuda E, Shimizu H, Kosaka T, Saito M.

    BMC Cancer.   14   550   2014.7

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI : 10.1186/1471-2407-14-550.

    PubMed

  • 【腹部救急疾患に対する内視鏡外科手術】 医原性大腸穿孔に対する腹腔鏡下手術

    吉川 征一郎, 福永 正氣, 李 慶文, 永仮 邦彦, 菅野 雅彦, 須田 健, 飯田 義人, 伊藤 嘉智, 大内 昌和, 勝野 剛太郎, 徳田 恵美, 平崎 憲範, 呉 一眞, 東 大輔

    日本腹部救急医学会雑誌   33 ( 1 )   55 - 59   2013.1( ISSN:1340-2242

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 【腹腔鏡下手術に伴う偶発症への対応】腹腔鏡下手術における術中出血に対する対処

    吉川征一郎, 福永正氣, 李慶文, 永仮邦彦, 菅野雅彦, 須田健, 飯田義人, 伊藤嘉智, 大内昌和, 勝野剛太郎, 徳田恵美, 平崎憲範, 夕部由規謙, 須貝歩

    日本腹部救急医学会雑誌   32 ( 1 )   43 - 47   2012.1

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • CA19-9産生乳癌の1例

    徳田恵美、阿部郁子、三浦弘善、堀本義哉、荒川 敦、白石昭彦, 齊藤 光江, 霞 富士雄

    乳癌の臨床   26 ( 4 )   481 - 485   2011.8

      More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  • 無症状の乳癌術後患者に対する骨シンチグラフィについての検討

    堀本 義哉, 徳田 恵美, 白石 昭彦, 中川 智恵, 小坂 泰二郎, 齊藤 光江, 霞 富士雄

    乳癌の臨床   25 ( 3 )   315 - 320   2010.7

      More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • 回腸憩室穿通による後腹膜膿瘍の1手術例

    徳田恵美, 杉崎勝好, 青木文夫, 保坂晃弘, 日吉雅也, 正木幸善.

    日本臨床外科学会雑誌   70 ( 7 )   2170 - 2173   2009.7

      More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 直腸癌術後孤立性副腎転移の1例

    徳田恵美, 板東隆文, 永岡栄, 杉崎勝好, 正木幸善, 武村民子.

    日本臨床外科学会雑誌   66 ( 11 )   2802 - 2806   2005.11

      More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • A case of multiple hepatic and peritoneal metastases from colon cancer responding to oral UFT+leucovorin chemotherapy

    Kiyoko Asai, Toyoki Fujita, Yuki Nakamura, Emi Tokuda, Masaya Hiyoshi, Fumio Aoki, Katsuyoshi Sugizaki, Yukiyoshi Masaki

    32 ( 12 )   1959 - 1961   2005.11

      More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

  • 分子標的としてのAktを介したシグナル伝達

    徳田恵美, 藤田直也, 鶴尾隆.

    治療学   38 ( 12 )   1327 - 1331   2004.12

      More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

▼display all

Books

  • 図解ですっきり!抗がん薬の薬理作用

    南博信・寺田智祐(4章ホルモン療法薬 ~性ホルモンが関わるがんへのホルモン供給を阻止 B. 乳がんに使用するもの a アロマターゼ阻害薬, プロゲステロン)

    南山堂  2023.7  ( ISBN:978-4-524-22817-1

     More details

    Responsible for pages:173-175   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:佐治重衡、徳田恵美   Publication place:  

  • 図解ですっきり!抗がん薬の薬理作用

    南博信・寺田智祐(4章ホルモン療法薬 ~性ホルモンが関わるがんへのホルモン供給を阻止 B. 乳がんに使用するもの b 抗エストロゲン薬)

    南山堂  2023.7  ( ISBN:978-4-524-22817-1

     More details

    Responsible for pages:176-178   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:佐治重衡、徳田恵美   Publication place:  

  • 図解ですっきり!抗がん薬の薬理作用

    南博信・寺田智祐(4章ホルモン療法薬 ~性ホルモンが関わるがんへのホルモン供給を阻止 A. 乳がん・前立腺がんに使用するもの a GnRHアゴニスト)

    南山堂  2023.7  ( ISBN:978-4-524-22817-1

     More details

    Responsible for pages:169-172   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:佐治重衡、徳田恵美   Publication place:  

  • トリプルネガティブ 乳癌Q&A

    大野真司・戸井正和(免疫チェックポイント阻害薬を用いる際のポイントについて教えてください(2)(*irAEの早期発見・早期対策))

    医歯薬出版株式会社  2023.7  ( ISBN:978-4-263-73214-4

     More details

    Responsible for pages:152-153   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美   Publication place:  

  • トリプルネガティブ 乳癌Q&A

    大野真司・戸井正和(免疫チェックポイント阻害薬を用いる際のポイントについて教えてください(2)(*毒性への対応) )

    医歯薬出版株式会社  2023.7  ( ISBN:978-4-263-73214-4

     More details

    Responsible for pages:154-155   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美   Publication place:  

  • 乳癌薬物療法の要点と盲点

    戸井雅和(監)、佐治重衡・増田慎三(編)(Ⅱ術前・術後薬物療法の要点と盲点B.内分泌法 2.タモキシフェン・トレミフェン)

    文光堂  2023.6  ( ISBN:978-4-8306-2264-9

     More details

    Responsible for pages:116-118   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美   Publication place:  

  • 乳癌薬物療法の要点と盲点

    戸井雅和(監)、佐治重衡・増田慎三(編)(Ⅲ進行・再発乳癌に対する薬物療法の要点と盲点C.HR陽性乳癌 2.タモキシフェン・トレミフェン)

    文光堂  2023.6  ( ISBN:978-4-8306-2264-9

     More details

    Responsible for pages:188-190   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美   Publication place:  

  • 治療戦略に役立つ臨床医病理医のための乳腺病理の見かた考え方

    増田慎三・堀井理絵(Ⅳ Biology評価 : Ki67の臨床的意義)

    メジカルビュー社  2022.11  ( ISBN:978-4-7583-1817-4

     More details

    Responsible for pages:138-142   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美、佐治重衡.   Publication place:  

  • 入門腫瘍内科学 改訂第3版

    日本臨床腫瘍学会(6.がん薬物療法 D内分泌療法)

    南江堂  2020 

     More details

    Responsible for pages:119-121   Language:Japanese   Book type:Scholarly book

    Authors name of the chapter and paper which it took charge of:徳田恵美、佐治重衡   Publication place:  

▼display all

Presentations

  • 当院における術前薬物療法を施行したTNBC(トリプルネガティブ乳癌)の検討

    第21回日本乳癌学会東北地方会   2024.3  

      More details

    Event date: 2024.3

  • Human leukocyte antigen(HLA) type as a possible predictive marker for thyroid immune-related adverse event

    2024.2  

      More details

    Event date: 2024.2

  • A case of early-stage breast cancer performed pituitary function test 4 years after the onset of pituitary irAE

    2024.2  

      More details

    Event date: 2024.2

  • 高齢者乳癌における乳房温存術後全乳房照射の意義 ―多施設共同後方視研究―

    第31回日本乳癌学会総会   2023.7  

      More details

    Event date: 2023.6 - 2023.7

  • 福島県におけるHBOC診療の現状報告と今後の課題

    第31回日本乳癌学会総会   2023.6  

      More details

    Event date: 2023.6 - 2023.7

  • 当院におけるがん遺伝子パネル検査にてPVPGを認めた症例への対応の現状とその課題

    第29回日本遺伝性腫瘍学会  

      More details

    Event date: 2023.6

  • Endocrine toxicities associated with Immune Checkpoint Inhibitors in breast cancer patients in our hospital.

    2023 the Japanese Society of Medical Oncology Annual Meeting -The 20th Anniversary Meeting-  

      More details

    Event date: 2023.3

  • The usefulness of pre-order medical record checking for the insurance civered Comprehensive Genomic Profiling test.

    2023 the Japanese Society of Medical Oncology Annual Meeting -The 20th Anniversary Meeting-  

      More details

    Event date: 2023.3

  • 当施設における乳癌診療の均てん化の試みと課題

    第20回日本乳癌学会東北地方会  

      More details

    Event date: 2023.3

  • TNBCに対する術前・術後免疫療法とirAE対策

    第20回日本乳癌学会東北地方会  

      More details

    Event date: 2023.3

  • Biology から考える Luminal-HER2 乳癌の治療戦略

    第30回日本乳癌学会総会  

      More details

    Event date: 2022.7

  • 高齢者乳癌患者の体型と病理学的因子および悪性度に関する検討

    第30回日本乳癌学会総会  

      More details

    Event date: 2022.6 - 2022.8

  • HLA遺伝子型を用いた免疫関連有害事象のナルコレプシー発症のリスク評価

    第119回日本内科学会総会  

      More details

    Event date: 2022.4

  • 免疫チェックポイント阻害薬を用いた乳癌術前治療の戦略ポイント

    第122回日本外科学会定期学術集会  

      More details

    Event date: 2022.4

  • Ubiquitin ligase NEDD4 promotes degradation of estrogen receptor in breast cancer and affects prognosis.

      More details

    Event date: 2022.2

  • Current status and research issues of late recurrence in breast cancer treatment.

      More details

    Event date: 2021.10

  • ER発現が低下した内分泌療法耐性乳癌細胞のER発現をPI3K阻害薬が再発現させる機序にエピゲノム変化が関与する

    第29回日本乳癌学会総会  

      More details

    Event date: 2021.7

  • ER陽性治療耐性乳癌細胞株においてドライバーシグナルはDNA損傷と修復に関与する

    第29回日本乳癌学会総会  

      More details

    Event date: 2021.7

  • Postoperative endocrine therapy for elderly patients could relate to overall survival or obesity

      More details

    Event date: 2021.7

  • がん遺伝子パネル検査を契機にBRCA 遺伝子に病的バリアントが検出された2症例.

    第27回日本遺伝性腫瘍学会  

      More details

    Event date: 2021.6

  • Research for onset mechanism of Multiple Myeloma. Can B cell-derived iPS cells redifferentiate into B cells?

      More details

    Event date: 2021.3

  • 妊娠中に周術期化学療法を行った乳癌患者への多職種連携支援の重要性

    第18回日本臨床腫瘍学会学術集会(JSMO2021)  

      More details

    Event date: 2021.3

  • 免疫チェックポイント阻害薬によるナルコレプシー発症のリスク

    第18回日本臨床腫瘍学会学術集会(JSMO2021)  

      More details

    Event date: 2021.3

  • 乳癌診療の新たな構築2020、

    第58回日本癌治療学会学術集会  

      More details

    Event date: 2020.10

  • Efficacy of Akt inhibitor Ipatasertib on various treatment-resistant model cells of ER positive BC.

      More details

    Event date: 2020.10

  • PI3K inhibitors restored the sensitivity to antiestrogen drugs in endocrine therapy resistant cells

      More details

    Event date: 2020.10

  • A retrospective study on the significance of perioperative chemotherapy for elderly patients.

      More details

    Event date: 2020.10

  • Prospects of Immunotherapy for Breast Cancer.

    The 79th Annual Meeting of the Japanese Cancer Association.  

      More details

    Event date: 2020.10

  • PI3K inhibitors restored the sensitivity to anti-estrogen drugs in endocrine therapy resistant cell lines.

    2019 San Antonio Breast Cancer Symposium  

      More details

    Event date: 2019.12

  • 耐性を考慮した乳癌治療戦略 耐性機序を想定した乳癌ホルモン療法(英語) SY12-2

    第57回日本癌治療学会学術集会  

      More details

    Event date: 2019.10

  • CDK4/6阻害剤耐性となった各種内分泌療法耐性乳癌細胞の細胞内リン酸化シグナルの変化と阻害剤耐性獲得後に有効な薬剤についての検討

    第17回日本臨床腫瘍学会学術集会  

      More details

    Event date: 2019.7

  • ニボルマブ治療中に免疫性血小板減少性紫斑病を発症し治療に難渋した一例

    第17回日本臨床腫瘍学会学術集会  

      More details

    Event date: 2019.7

  • 当院における高齢者HER2陽性進行再発乳癌に対するT-DM1療法の忍容性に関する検討

    第17回日本臨床腫瘍学会学術集会  

      More details

    Event date: 2019.7

  • 東日本大震災前後における福島県の部位別年齢階級別罹患率の動向〜がん検診を行っている5部位について〜(第2報)

    第17回日本臨床腫瘍学会学術集会  

      More details

    Event date: 2019.7

  • PI3K-mTOR経路阻害薬はERが陰転化した内分泌療法耐性乳癌細胞株の抗エストロゲン薬の感受性を回復させる

    第27回日本乳癌学会学術総会  

      More details

    Event date: 2019.7

  • エストロゲン受容体陽性進行再発乳癌治療薬への耐性獲得後の上皮間葉転換及び癌幹細胞性形質変化

    第27回日本乳癌学会学術総会  

      More details

    Event date: 2019.7

  • CDK4/6阻害剤の薬剤による耐性メカニズムの相違点の検討

    第27回日本乳癌学会学術総会  

      More details

    Event date: 2019.7

  • ER陽性乳癌細胞の分子標的薬耐性獲得に際したDNA修復機構の変化とPARP阻害薬適応の可能性の検討

    第27回日本乳癌学会学術総会  

      More details

    Event date: 2019.7

  • 乳癌治療におけるCDK4/6阻害剤の可能性

    第119回日本外科学会定期学術集会  

      More details

    Event date: 2019.4

▼display all